BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Announces $300K Private Placement and Warrant Extension

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on imaging-based products for breast cancer care, announced plans for a non-brokered private placement of up to 1.2 million units at $0.25 each to raise gross proceeds of up to $300,000. Each unit will include one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. The Company also extended the expiry of 2,841,325 warrants issued in September 2023 by one year to September 20, 2026, with all other terms unchanged. The warrant extension remains subject to final CSE approval.

To view the full press release, visit https://ibn.fm/kV1Wl

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds Scalable Business Through Vertical Integration, Dual-Market Strategy

Earth Science Tech (OTC: ETST) is building a scalable, self-sustaining healthcare business through strategic acquisitions, end-to-end…

2 days ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee…

3 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research…

5 days ago

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer

Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2…

5 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its…

6 days ago